4.6 Article

AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer's drug discovery

期刊

ALZHEIMERS RESEARCH & THERAPY
卷 13, 期 1, 页码 -

出版社

BMC
DOI: 10.1186/s13195-020-00760-w

关键词

Alzheimer's disease; Clinical trial; Drug repurposing; Genomics; Mechanism-of-action; Multi-omics; Network medicine; Systems pharmacology

资金

  1. National Institute of Aging (NIA) [R01AG066707, 3R01AG066707-01S1, R01AG053798, R56AG063870]
  2. Translational Therapeutics Core of the Cleveland Alzheimer's Disease Research Center (NIH/NIA) [1 P30 AGO62428-01]
  3. Brockman Foundation
  4. AHA/Allen Initiative in Brain Health and Cognitive Impairment [19PABH134580006]
  5. Elizabeth Ring Mather & William Gwinn Mather Fund
  6. S. Livingston Samuel Mather Trust
  7. G.R. Lincoln Family Foundation
  8. Wick Foundation
  9. Gordon Evie Safran
  10. Leonard Krieger Fund of the Cleveland Foundation
  11. Maxine and Lester Stoller Parkinson's Research Fund
  12. Louis Stokes VA Medical Center
  13. Alzheimer's Drug Discovery Foundation
  14. Cleveland Clinic Lerner Research Institute
  15. Department of Defense
  16. Douglas Herthel DVM Memorial Research Fund
  17. Eisai
  18. GE Healthcare
  19. Jane and Lee Seidman Fund
  20. Lewy Body Dementia Association
  21. Michael J Fox Foundation
  22. NIH/NIA funds [P30 AG062428, UO1 NS100610, RO1 AG022304, RO1 AG0577552, RO3 AG063235, R21 AG064271, P20 AG068053]
  23. Sanofi
  24. Keep Memory Alive (KMA)
  25. NIGMS grant [P20GM109025]
  26. NINDS [U01NS093334]
  27. NIA [R01AG053798]

向作者/读者索取更多资源

AlzGPS is a comprehensive systems biology tool that integrates multi-omics data and biological networks to identify therapeutic targets for Alzheimer's disease, provide potential treatment information, and establish links between drugs and disease modules. This tool also includes information from over 1000 clinical trials to accelerate therapeutic development for Alzheimer's disease.
Background: Recent DNA/RNA sequencing and other multi-omics technologies have advanced the understanding of the biology and pathophysiology of AD, yet there is still a lack of disease-modifying treatments for AD. A new approach to integration of the genome, transcriptome, proteome, and human interactome in the drug discovery and development process is essential for this endeavor. Methods: In this study, we developed AlzGPS (Genome-wide Positioning Systems platform for Alzheimer's Drug Discovery, ), a comprehensive systems biology tool to enable searching, visualizing, and analyzing multi-omics, various types of heterogeneous biological networks, and clinical databases for target identification and development of effective prevention and treatment for AD. Results: Via AlzGPS: (1) we curated more than 100 AD multi-omics data sets capturing DNA, RNA, protein, and small molecule profiles underlying AD pathogenesis (e.g., early vs. late stage and tau or amyloid endophenotype); (2) we constructed endophenotype disease modules by incorporating multi-omics findings and human protein-protein interactome networks; (3) we provided possible treatment information from similar to 3000 FDA approved/investigational drugs for AD using state-of-the-art network proximity analyses; (4) we curated nearly 300 literature references for high-confidence drug candidates; (5) we included information from over 1000 AD clinical trials noting drug's mechanisms-of-action and primary drug targets, and linking them to our integrated multi-omics view for targets and network analysis results for the drugs; (6) we implemented a highly interactive web interface for database browsing and network visualization. Conclusions: Network visualization enabled by AlzGPS includes brain-specific neighborhood networks for genes-of-interest, endophenotype disease module networks for omics-of-interest, and mechanism-of-action networks for drugs targeting disease modules. By virtue of combining systems pharmacology and network-based integrative analysis of multi-omics data, AlzGPS offers actionable systems biology tools for accelerating therapeutic development in AD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据